Abstract: Compounds capable of binding to granzyme B and comprising a radioactive moiety, for examples, compounds of Formula (I), and pharmaceutical compositions comprising such. Also provided herein are uses of the compounds and pharmaceutical composition in cancer treatment and/or imaging.

Abstract: Compounds capable of binding to granzyme B and comprising a radioactive moiety, for examples, compounds of Formula (I), and pharmaceutical compositions comprising such. Also provided herein are uses of the compounds and pharmaceutical composition in cancer treatment, and kits and methods for cancer therapy.

Abstract: The present application discloses a scanning electron microscopic direct-write lithography system based on a compliant nano servo motion system, which includes an electron chamber, an ion chamber, a specimen chamber and a control system, wherein the electron chamber includes an electron chamber housing, an electron gun, an anode, an electron beam blanker, an electromagnetic lens and an electron beam deflection coil, the ion chamber includes an ion chamber housing, an ion source, an ion beam-scanning deflection electrode and the like, the specimen chamber includes a specimen chamber housing, a secondary electron detector, a nanoscale-precision compliant servo motion stage system and the like; control system includes a computer, an electron beam scanning controller, an ion beam scanning controller and the like.

Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.

Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.

Abstract: The present invention relates to stereo isomers of C5-hydroxyl substituents, N-substituted derivatives of hydroxybenzyl, hydroxyl, phenyl substituted ?-lactams (clausenamide) and the preparation methods thereof, and pharmaceutical compositions containing the same and their uses for the preparation of medicaments as nootropic and anti-aging drugs.

Abstract: The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.

Abstract: The invention relates to compounds of formula (I): wherein R1 represents alkyl or ureido, R2 represents alkyl or hydrogen, or R1 and R2 together form a 5- or 6-membered ring, R3 represents CN, NO2, NRaR′a, NRaSO2R′a, NRaCZR5 or CZNRaR′a, R4 represents hydrogen or R3, and medicinal products containing the same which are useful in treating or preventing epilepsy and neurodegenerative diseases.

Abstract: The invention relates to compounds of formula (I): wherein R1 represents an alkyl or ureido group, R2 represents an alkyl group or a hydrogen atom, or R1 and R2 together form a 5- or 6-membered ring, R3 represents a group CN, NO2, NRaR′a, NRaSO2,R′aCZR5 or CZNRaR′a, R4 represents a hydrogen atom or a group R3.

Abstract: The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.